Zentalis Pharmaceuticals (ZNTL) Income from Continuing Operations (2019 - 2026)
Zentalis Pharmaceuticals' quarterly Income from Continuing Operations came in at 35352000.0 in Q1 2026, up 26.78% year-on-year from 27885488.48 in Q1 2025, and little changed quarter-over-quarter from 35216000.0 in Q4 2025.
Zentalis Pharmaceuticals has reported Income from Continuing Operations for 8 years, with the latest figure at 35352000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 26.78% year-over-year to 35352000.0; the trailing twelve-month figure through Mar 2026 stood at 124133000.0 (up 44.63% YoY), and the FY2025 full-year result was 137060000.0, up 17.37% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 35352000.0, roughly flat from 35216000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 10040000.0 in Q1 2024, with the low at 98860000.0 in Q2 2023.
- Average Income from Continuing Operations over 5 years is 49141235.29, with a median of 48279000.0 recorded in 2025.
- Year-over-year, Income from Continuing Operations jumped 116.47% in 2024 and tumbled 580.87% in 2025.
- Tracing ZNTL's Income from Continuing Operations over 5 years: stood at 48162000.0 in 2022, then slipped by 26.53% to 60939000.0 in 2023, then advanced by 22.1% to 47472000.0 in 2024, then gained by 25.82% to 35216000.0 in 2025, then fell by 0.39% to 35352000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 35352000.0 (Q1 2026), 35216000.0 (Q4 2025), and 26691000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | -35.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.35 Mn |
| Dec 31, 2025 | -35.22 Mn |
| Sep 30, 2025 | -26.69 Mn |
| Jun 30, 2025 | -26.87 Mn |
| Mar 31, 2025 | -48.28 Mn |
| Dec 31, 2024 | -47.47 Mn |
| Sep 30, 2024 | -40.16 Mn |
| Jun 30, 2024 | -88.28 Mn |
| Mar 31, 2024 | 10.04 Mn |
| Dec 31, 2023 | -60.94 Mn |
| Sep 30, 2023 | -55.54 Mn |
| Jun 30, 2023 | -98.86 Mn |
| Mar 31, 2023 | -60.95 Mn |
| Dec 31, 2022 | -48.16 Mn |
| Sep 30, 2022 | -52.13 Mn |
| Jun 30, 2022 | -63.05 Mn |
| Mar 31, 2022 | -57.49 Mn |
| Dec 31, 2021 | -48.26 Mn |
| Sep 30, 2021 | -10.49 Mn |
| Jun 30, 2021 | -55.06 Mn |
| Mar 31, 2021 | -50.44 Mn |
| Dec 31, 2020 | -40.36 Mn |
| Sep 30, 2020 | -34.67 Mn |
| Jun 30, 2020 | -27.29 Mn |
| Mar 31, 2020 | -16.24 Mn |
| Dec 31, 2019 | -14.55 Mn |
| Sep 30, 2019 | -12.57 Mn |
| Jun 30, 2019 | -10.60 Mn |
| Mar 31, 2019 | -8.66 Mn |